

## EXTRAORDINARY LAMINAR PHARMACEUTICALS S.A. SHAREHOLDERS' MEETING CALL

I hereby call the general Laminar Pharmaceuticals S.A. shareholders' meeting that will take place at ParcBit, Ctra. Valldemossa km 7.4, Press Room (Centre Empresarial Son Español), on June 20<sup>th</sup>, 2024, at 11:00 a.m., with the aim to discuss and make a decision on the following issues:

### AGENDA

1. Examination and approval, if applicable, of the Company Accounts corresponding to the fiscal year ended December 31, 2023.
2. Examination and approval, if applicable, of the Proposal for the Application of the Result corresponding to the fiscal year ended on December 31, 2023.
3. Censorship of the corporate management corresponding to the fiscal year ended on December 31, 2023.
4. Appointment of Auditors.
5. Establishment of the number of members of the Board of Directors. Appointment of new Directors.
6. Examination and approval, if applicable, of the Directors' Compensation.
7. Authorization for the Company to proceed with the acquisition of its own shares.
8. Ratification of the incentive plan for the Company's workers and service providers.
9. Requests and questions.
10. Delegation of Powers.
11. Reading and approval of the minutes of the meeting.

I will recall your right to be informed about the points listed in the agenda, according to the current regulatory frame. This information is available at Laminar's website, [www.laminar.com](http://www.laminar.com), which consists of the following documents:

- The Annual Accounts of the Company corresponding to the year ended December 31, 2023, together with the respective voluntary audit report,
- Proposals from the Board of Directors on the items on the agenda and, where applicable, (i) the full text of the proposed statutory modifications, (ii) Directors' report on the proposed statutory modifications,
- Voting Delegation Document, and

- Remote Voting Document.

You can also receive from Laminar this information sending an email to [inversores@laminarpharma.com](mailto:inversores@laminarpharma.com)

With respect to the remote voting form, vote delegation and online assistance we are pleased to provide the following information:

#### **Right to Assistance:**

In accordance with article 17 of the Company's Bylaws, the Shareholders will have the right to attend the Extraordinary General Meeting of Shareholders, provided that they are holders of at least 5,000 shares and that prior to the holding of the Meeting the shareholder legitimacy. Shareholders holding a smaller number of shares may delegate their representation in favor of a shareholder with the right to attend, as well as group with other shareholders in the same situation until they gather the necessary shares, with the grouped shareholders having to grant their representation to one of them. The grouping must be carried out on a special basis for each Shareholders' Meeting and be recorded in writing. In the case of a Legal Entity, the representative natural person must prove the powers granted sufficient for their representation.

Therefore, it will be a requirement to attend the Ordinary and Extraordinary General Meeting of Shareholders that the shareholder has their shares registered in the Register of Nominative Shares.

Regarding remote voting, voting delegation and telematic attendance at the Meeting, the following is reported:

#### **Remote Voting**

According to Art. 17.5 of Laminar's Articles of Organization, shareholders can vote proposals included in the Agenda previously to the Shareholders' Meeting as far as the shareholders provides a proof of identity (for example using the email address provided to Laminar). To this end, shareholders can use Laminar's website via a link provided in the call's email.

All shareholders with the right of attendance and vote may vote on the proposals related to the points indicated in the Agenda using the following means:

- a) Postal correspondence addressed to Laminar's postal address, sending the corresponding Remote Vote, signed with a readable copy of an ID that could allow the shareholder's identity matching.
- b) By email sent to [inversores@laminarpharma.com](mailto:inversores@laminarpharma.com), using the email address already communicated to Laminar, in agreement with Art. 7 of the Articles of Organization.

Such a vote will be valid only when received at least 3 days prior to the Shareholders' Meeting. In the case a shareholder wants to change his/her vote, this new position will be valid if received after

the first vote and using the same means indicated above with the same time restriction (3 days before the Meeting).

### **Right of Representation.**

According to the Articles of Organization, shareholders can be represented by another person, not necessarily a shareholder, by means of a person acting of a proxy holder for one or more shareholders by means of a written document specifically prepared for each meeting. In this context, shareholders can use the form provided in Laminar's website, which has to be signed up by the representative and sent to Laminar at least 2 hours before the meeting with a copy of an ID or passport of the representative.

The representation delegation issued by a shareholder before the distance vote will be considered revoked and those issued after the delegation will be considered not done. Personal attendance to the General Meeting of a shareholder who previously delegated its representation overcomes said delegation.

### **Telematic attendance**

Under Art. 17.5 of Laminar's Articles of Organization, the company will consider valid the attendance and vote issued by telematic means, as far as the shareholder is duly identified and the vote is duly registered in agreement with Art. 182 from the Capital Societies Law.

The telematic procedure is detailed below:

- a) Previous registration: Shareholders who wish to attend using this means must register via email, using the email address provided to Laminar according to Art. 7 of the Articles of Organization, sent to [inversores@laminarpharma.com](mailto:inversores@laminarpharma.com) from the publication of the call until 5 days before the Meeting. In the case of representatives, they must register, within the same period of time, sending a copy of the ID, a copy of the represented shareholder's ID or its CIF/VAT/NIE, along with the representation document duly signed by both.
- b) Connection and telematic attendance: Previous to the Shareholders' Meeting, those who have previously registered and after confirmation of their legitimate right of attendance, will receive an email to the address used for previous registration, with a link to join to the meeting by videoconference, so that internet connection is necessary and the indicated software should be installed on the computer.
- c) Intervention: Interventions and proposals of agreements or requests of information or clarifications that, in agreement with the law, are intended to be performed by those who attend using telematic means must be emailed to the Society using the same email address used in the previous registration and, in all cases, at least 72 hours previous to the Meeting. Unless the number of telematic attendants makes it possible, telematic interventions will not be responded, although within the seven days following the Meeting Laminar's administrators may provide using written means the information requested that could not be given at the moment of the Meeting.

- d) **Telematic Vote:** On the one hand, the vote on proposals of issues included in the Agenda can be sent remotely, according to the specifications that will be indicated in the General Shareholders' Meeting, using the email address [inversores@laminarpharma.com](mailto:inversores@laminarpharma.com), or by a system specifically established to that end. On the other hand, the vote on proposals not included in the Agenda must be issued in the period of time indicated by the President of the General Meeting upon proposal formulation and determination of the need of submission to voting.

Inclusion of shareholders attending remotely in the list of attendants will be done with (i) the reception of the remote vote in the time and form established, or (ii) upon its access to the session follow-up platform with the required anticipation and after identity confirmation.

If for whatever technical or safety reasons derived from unexpected circumstances, a communication shut down occurred, or if it was impossible telematic attendance, such circumstance will be ascribed neither as deprivation of rights of the shareholder nor as cause of impugnation of agreements made in the General Meeting.

**Personal data protection:**

All the data provided by the Shareholders will be used exclusively for the purpose of holding the aforementioned General Meeting, based on the contractual relationship or express consent failing that. No data will be transferred to third parties, except legal obligation, nor will international transfers be made.

Interested parties may exercise their rights of access, rectification, deletion, or limitation of treatment, by contacting the following address: Address: ParcBit, Ctra. de Valldemossa Km 7.4, Parc Bit, Calle Isaac Newton Edificio Naorte Block A, 1st floor, door 3, Palma de Mallorca. You can access more information by referring to the privacy policy available at: <https://laminarpharma.com/legal-cast/>. Likewise, you can file a claim with the Spanish Agency for Data Protection if you consider that your rights have been violated.

Palma de Mallorca, May 8<sup>th</sup>, 2024

The President

Mr. José Antonio Sánchez Vicent